LOS ANGELES, CA--(Marketwire - Jul 21, 2011) - MMRGlobal, Inc. (OTCBB: MMRF), a leading provider of health IT products and services, including the MyMedicalRecords Personal Health Record (PHR) for use by consumers and healthcare professionals and MMRPro for physicians and hospitals, today announced that the Company and Unis-Tonghe Technology (Zhengzhou) Co., Ltd., MMR'S Chinese Joint Venture partner, have entered into a series of warrant purchase agreements whereby Unis-Tonghe has the right to purchase up to four (4) million shares of the Company's common stock: one million at 8 cents per share, an additional million shares at 12 cents per share, an additional million at 16 cents per share, and one million at 20 cents per share.

"This is a demonstration of Unis-Tonghe's commitment to the relationship with MMRGlobal," said Robert H. Lorsch, Chairman and CEO of MMRGlobal, Inc. "The Chinese government is serious about health IT and enrolling their population of over 1.3 billion in safe, secure and cost-efficient eHealth programs to protect the health of their citizens and reduce healthcare costs in the future. Our joint plans include a customized version of MMR's proprietary Personal Health Record and professional document imaging and management solutions which are embedded in MMRPro." (visit http://www.mmrprovideos.com)

Initial programs call for the provision of a variety of EMR services in Henan Province, one of the most populous provinces in China with nearly 100 million citizens. The province reportedly has 1410 municipal health institutions, including 164 hospitals, 43 community health centers, 134 community health stations, 14 women's and children's health maintenance centers, 17 disease prevention and control centers, seven health supervision stations and 42,231 healthcare professionals that include 16,389 assistant doctors and 16,432 registered nurses.

Unis-Tonghe recently received official notice that they are a winner of a bid to provide eHealth and Electronic Medical Record Services for 164 County/District of Henan Province in China. MMRGlobal announced the signing of a definitive agreement with Unis-Tonghe to be joint venture partners in January 2010. The Company believes that certain features and processes created for MMRPro and the MyMedicalRecords Personal Health Record may be incorporated into the Henan Province program on the Unis Medical Clouds Service. Further information is available in Chinese at: http://www.hngp.gov.cn/henan/cgxx/jggg/webinfo/2011/06/17/1307675575801256.htm)

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR") (www.mymedicalrecords.com), provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements update

Statements in this press release that are not strictly historical in nature, including future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Factors that could cause or contribute to such differences include, but are not limited to, the risk the Company's products are not adopted or viewed favorably by the healthcare community; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; product integration in physician practices and hospitals; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product introductions; competitive offerings; ability to establish and maintain strategic relationships; the outcome of our joint venture agreements; ability to identify and integrate acquisitions; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry, both nationally and abroad; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; acceptance of the Company's marketing and promotional campaigns; risks related to a security breach by third parties; maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets; risks associated with recruitment and retention of key personnel; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. Additionally, we are a developing early-stage company and many variables can affect revenues and/or projections, including factors out of our control. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact Information:


Michael Selsman
Public Communications Co.
(310) 553-5732